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5-HT = 5-hydroxytryptamine; 5-HTT = 5-hydroxytryptamine transporter; PH = pulmonary hypertension; SMC = smooth muscle cell.
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Introduction
Appetite suppressant use is now considered an important
risk factor for the development of primary PH. An associa-
tion between the anorexigen aminorex and PH was first
reported in the 1960s, and aminorex was withdrawn from
the market in 1972 [1]. In the 1980s, fenfluramine use
was linked to primary PH and, subsequently, a 30-fold
increase in the risk of PH was found in patients who had
received these appetite suppressants for longer than
3 months compared with the general population [2,3].
Understanding the molecular mechanism of appetite-sup-
pressant-induced PH has become a major goal for current
and future studies. Because amphetamine-like drugs have
potential applications in the treatment of obesity, drug
dependence, and other psychiatric disorders, a legitimate
concern is that new members of this class introduced in
the future might cause outbreaks of PH similar to those
seen with aminorex and fenfluramine. To ward off this
danger, we must identify the drug-related effects likely to
generate PH and/or the patient characteristics associated
with susceptibility to these effects.
Better knowledge of the pathobiology of primary PH can
be expected to flow from elucidation of the mechanisms
underlying appetite-suppressant-induced PH. These drugs
promote the development of vascular lesions confined to
the small muscular arteries and arterioles in the lung, sug-
gesting that one of their molecular targets may be selec-
tively present in pulmonary vessels or may have specific
functions in pulmonary vessels compared with systemic
vessels. Aminorex, fenfluramine, D-fenfluramine, and phen-
termine belong to a vast class of amphetamine-like drugs
that interact with monoamine systems in the brain. Among
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appetite suppressants, however, only fenfluramine, D-fen-
fluramine, and aminorex increase the risk of primary PH.
The fact that these three drugs not only inhibit neuronal
serotonin (5-HT) reuptake, but also trigger indoleamine
release has sparked renewed interest for the ‘serotonin
hypothesis’ of PH.
In our laboratory, we recently tested the hypothesis that
the 5-HT transporter (5-HTT) in the lung might be a key
determinant of pulmonary vessel remodeling because of
its action on pulmonary artery smooth muscle cell (SMC)
growth [4]. The 5-HTT transporter is abundantly
expressed in the lung, where it is predominantly located
on SMCs [5]. The recent observation that aminorex and
fenfluramine derivatives interact with 5-HTT in a specific
manner has provided further support to the hypothesis
that this transporter may be a critical target for appetite
suppressants and perhaps for other insults initiating the
process of PH [6].
5-HTT as a key determinant of pulmonary
vascular remodeling
A pathological feature shared by secondary and primary
PH is increased thickness of the distal pulmonary artery
walls, related chiefly to SMC hyperplasia [7]. The 5-HTT in
pulmonary vascular SMCs has many attributes suggesting
that it may be a key determinant of this process. In addi-
tion to contributing to the uptake and subsequent inactiva-
tion of 5-HT passing through the lung, 5-HTT mediates the
proliferation of pulmonary vascular SMCs through its
ability to internalize indoleamine [4,8,9]. The level of 5-HTT
expression appears to be much greater in human lung
than in human brain, suggesting that altered 5-HTT
expression may have direct consequences on pulmonary
artery–SMC function [5]. Direct evidence that 5-HTT plays
a key role in pulmonary vascular remodeling was recently
obtained by showing that mice with targeted 5-HTT gene
disruption develop less severe hypoxic PH than wild-type
controls [10], and that selective 5-HTT inhibitors attenuate
hypoxic PH. Conversely, increased 5-HTT expression is
associated with increased severity of hypoxic PH [11].
Although a heterogeneous population of 5-HT2A and 5-
HT1B receptors coexist in pulmonary arteries, 5-HT
receptor antagonists do not seem to efficiently protect
against development of hypoxic PH (unpublished data).
Taken together, these observations suggest a close corre-
lation between 5-HTT expression and/or activity and the
extent of pulmonary vascular remodeling during exposure
to hypoxia.
5-HTT expression and activity are also increased in
platelets and lungs from patients with primary and sec-
ondary forms of PH [12] and in pulmonary artery SMCs
from patients with primary PH, as compared with SMCs
from controls. Furthermore, compared with SMCs from
controls, SMCs from PH patients are more susceptible to
the growth promoting effects of 5-HT and serum (which
contains high levels of 5-HT) [12], whereas there is no dif-
ference for other growth factors such as platelet-derived
growth factor, transforming growth factor-β, fibroblast
growth factor-a, and epidermal growth factor. In the pres-
ence of 5-HTT inhibitors, the growth stimulating effects of
serum and 5-HT are markedly reduced, and the difference
between growth of SMCs from patients and controls is
abolished. It follows that 5-HTT overexpression and/or
activity in pulmonary artery SMCs from patients with PH is
responsible for the increased mitogenic responses to
5-HT and serum [13].
Mechanisms by which appetite suppressants
may promote primary PH: is 5-HTT a critical
target for drugs linked to primary PH?
5-HT turnover alteration
The anorexigens aminorex, fenfluramine, and dexfenflu-
ramine are potent 5-HT uptake inhibitors. This inhibition
occurs not only in neurons of the serotoninergic category,
but also in platelets, pulmonary endothelial cells and
SMCs, which share the same 5-HTT encoded by a single
gene [14]. These facts initially led to the hypothesis that
fenfluramine-like medications may elevate circulating 5-HT
levels [15,16], which in turn may increase pulmonary
artery pressure and pulmonary artery SMC growth,
thereby producing primary PH in susceptible individuals.
This ‘serotonin hypothesis’ was consistent with reports of
increased plasma 5-HT levels under several conditions
leading to PH [17,18]. Recent findings, however, run
counter to the serotonin hypothesis: chronic treatment
with phentermine and fenfluramine in combination
decreases plasma 5-HT levels in humans [19]. Another
argument against the serotonin hypothesis is that 5-HTT is
also the target of widely used antidepressants, such as
selective 5-HT reuptake inhibitors and conventional tri-
cyclic antidepressants, which do not promote the develop-
ment of primary PH. Conversely, selective 5-HTT inhibitors
attenuate the development of experimental PH. Moreover,
preliminary data from a case–control study performed in
Europe has suggested that the psychoanaleptic drugs
may lower the odds ratio for primary PH [20].
The 5-HT concentrations in blood and plasma may not,
however, be indicative of 5-HT concentrations in local
microenvironments surrounding pulmonary endothelial
cells or SMCs. In addition to their 5-HTT inhibiting proper-
ties, aminorex and fenfluramine-like drugs are potent trig-
gers of indoleamine release and, consequently, increase
the amount of extracellular 5-HT [6]. Selective 5-HTT
inhibitors also increased 5-HT levels in extracellular fluid,
but to a much smaller degree than fenfluramine-like drugs
[21]. This leaves open the possibility that these drugs may
promote 5-HT turnover alterations, thereby increasing the
availability of free 5-HT near the pulmonary artery wall.
Since 5-HT is also released from pulmonary neuro-
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endocrine cells and neuroepithelial bodies distributed
throughout the airways, and possibly from pulmonary
artery SMCs [22], this makes 5-HT more likely to have a
role on pulmonary compared with systemic vessels.
Interaction with 5-HTT
Recent studies investigated the possibility that fenflu-
ramine and other anorexigens might increase the risk of
primary PH by interacting directly with 5-HTT. Interest-
ingly, drugs known or suspected to increase the risk of
primary PH (namely, aminorex, fenfluramine, and chlor-
phentermine) were found to be 5-HTT substrates,
whereas drugs not associated with an increased risk of
primary PH were less potent in this regard [6]. It has been
speculated that medications that are 5-HTT substrates
may be translocated into pulmonary cells where, depend-
ing on the degree of drug retention, intrinsic drug toxicity,
and individual patient susceptibility, they may cause
effects similar to or greater than those of 5-HT [6].
According to this hypothesis, 5-HTT substrates other than
5-HT may also be mitogenic. Support for this hypothesis
has come from a recent study showing that fenfluramine is
mitogenic for rat lung SMCs and for lung fibroblasts [9].
Potassium-channel inhibition has also been suggested as
a potential mechanism of anorexigen-induced cell toxicity
[22]. Although this effect requires drug concentrations 10
times greater than those expected with therapeutic drug
dosages, it remains plausible that direct vasoconstriction
related to potassium-channel blockade or increased intra-
cellular Ca2+ levels in SMCs may contribute to the toxic
effects of appetite suppressants after internalization and
accumulation of these drugs by the SMCs. The fact that
5-HT uptake inhibitors and substrates may bind to differ-
ent domains on 5-HTT suggest that determining the exact
mechanism of action of each drug may help to predict the
risk of adverse effects [6].
Stimulation of 5-HTT expression
Another mechanism by which anorexigens may promote
pulmonary vascular remodeling is stimulation of 5-HTT
expression. Previous studies have shown that hormones
and pharmacological agents [23] can modulate 5-HTT
levels and activity in serotoninergic neurons. Dexfenflu-
ramine given in high doses has been shown to produce
long-lasting decreases in both concentration and uptake
of 5-HT in forebrain regions, as well as in 5-HTT mRNA
levels within the dorsal raphe nucleus [24]. We found that
the levels of 5-HTT transcript in lung tissue from rats given
chronic dexfenfluramine treatment for 4 weeks remained
unchanged compared with those in animals treated with
the vehicle alone. However, discontinuation of chronic
dexfenfluramine treatment in rats was followed by
increased lung 5-HTT expression, which promoted the
development of hypoxic PH [25]. 5-HTT overexpression
such as that induced by withdrawing dexfenfluramine-like
drugs may therefore represent a complementary mecha-
nism promoting 5-HTT-dependent hyperplasia of pul-
monary SMCs.
Genetic susceptibility to anorexigen-induced
PH
A genetic predisposition has been postulated to explain
why primary PH develops in only a minority of appetite-
suppressant users. In keeping with this possibility, feeding
aminorex or dexfenfluramine to experimental animals fails
to elicit PH. Interestingly, it has been established that
5-HTT expression is genetically controlled: a polymor-
phism in the promoter region of the human 5-HTT gene
alters transcriptional activity. This polymorphism consists
of two common alleles, a 44 base pair insertion (the L
allele) or deletion (the S allele) [25]. The L allele drives a
twofold to threefold higher level of 5-HTT gene transcrip-
tion than the S allele. Preliminary results suggest that the
L/L genotype is present in 60–70% of the patients with
PH as compared with only 20–30% of a control popula-
tion of Caucasian subjects [13]. The L/L genotype may
therefore confer genetic susceptibility to PH in humans,
particularly when it is combined with other factors such as
hypoxia, HIV infection, portal hypertension, or other condi-
tions. Individuals with a high basal level of 5-HT uptake
related to presence of the long 5-HTT gene promoter
variant may be particularly susceptible to one or more of
the aforementioned potential mechanisms of appetite-sup-
pressant-related primary PH. Studies examining the poten-
tial association between appetite-suppressant-related PH
and 5-HTT gene polymorphism are warranted.
In recent studies, mutations in the coding sequence of the
BMPR2 gene were shown to occur in more than 50% of
patients with familial primary PH and in at least 25% of
patients with sporadic primary PH [26,27]. The functional
impact of BMPR2 mutations into the pathogenesis of pul-
monary vascular remodeling is presently under investiga-
tion. An attractive hypothesis is that dysfunction of the
BMPR2 protein may result in impaired control of cellular
proliferation or gene transcription. Whether abnormal sig-
naling through mutated BMPR2 may contribute to appetite-
suppressant-related PH also remains to be determined.
Conclusion
The observation that 5-HTT polymorphism may confer sus-
ceptibility to primary PH suggests a mechanism by which
appetite suppressants may increase the risk of primary PH
in humans. Fenfluramine-like medications may contribute
to PH by elevating circulating 5-HT levels, they may act as
5-HTT substrates to produce the same effect as 5-HT or
they may alter 5-HTT expression. Individuals with a high
basal serotonin uptake that is related to the presence of
the long 5-HTT gene promoter variant might be particularly
susceptible to one or more of these potential mechanisms
of appetite-suppressant-related primary PH.
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